MedTrace Logo

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 682

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

Conditions

  • Macular Edema, Cystoid
  • Retinal Vein Occlusion

Interventions

OTHER

Standard Care

CRVO: observation; BRVO: standard care

DRUG

intravitreal triamcinolone injection

1 mg dose

DRUG

intravitreal triamcinolone injection

4 mg

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Allergan

    collaborator INDUSTRY

  • The Emmes Company, LLC

    lead INDUSTRY

Principal Investigators

  • Michael S. Ip, M.D. · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00105027 on ClinicalTrials.gov